Angiopoietin-1 for Myocardial Angiogenesis
Vien Khach Lai, Muhammad Zeeshan Afzal, Muhammad Ashraf and Khawaja Husnain Haider
Department of Pathology
University of Cincinnati, Cincinnati, OH, USA

1. Introduction
In response to ischemic damage, the heart undergoes vicious process of remodeling wherein the damaged myocardium is replaced by scar tissue and as compensatory mechanism, its existing collateral vessels and neovascularization with concomitant changes in cell recruitment, multiplication and cytokine/growth factor action. Angiogenesis is a complex process which involves an interplay between multiple pro- and anti-angiogenic factors and a harmonized interaction between endothelial progenitor cells, smooth muscle cells, pericytes and supportive environment. Besides Vegf/ Vegf receptor system, angiopoietin family of pro-angiogenic growth factors in conjunction with their receptor system are critical for vascular protection, remodeling, proliferation and maturation beside preservation of the integrity of newly formed vascular structures for functional activity (Thurston et al. 2000; Saharinen et al. 2005; Brindle, Saharinen et al. 2006).

An outside intervention to support the inefficient intrinsic myocardial repair processes by administration of stem/ progenitor cells has emerged as a promising strategy for the treatment of ischemic heart diseases. The transplanted stem cells have shown both myogenic as well as vasculogenic differentiation potential and participate in the myocardial regeneration via angiomyogenesis (Chen et al. 2010; Uemura et al. 2006; Eguchi et al. 2007).

In addition to differentiation, stem cells can also ameliorate inflammation, migrate to ischemic regions and secrete bioactive molecules as a part of their paracrine activity and significantly contribute myocardial protection and angiogenesis. Alternatively, multimodal therapeutic strategies have also been adopted to accentuate the angiomyogenic potential of stem cells. This includes preconditioning of stem cells with growth factor treatment, their genetic modification with plasmids encoding for various angiogenic growth factors and concomitant administration of recombinant angiogenic growth factor proteins (Jiang et al. 2006; Haider et al. 2008; Kim et al. 2009; Lu et al. 2009). Such multimodal treatment strategies have elicited beneficial effects in terms of improving stem cell survival and enhancing their paracrine behavior besides stimulation of angiogenesis through direct recruitment, proliferation and maturation of precursor cells such as endothelial progenitor cells, mesenchymal stem cells and monocytes to the ischemic heart (Banai et al. 1994; Hiasa et al. 2004; Elmadbouh et al. 2007; Haider et al. 2008). We discuss here the biological regulation of angiopoietin-1 expression, its interaction with specific receptor system and the advantages of transgenic over expression of angiopoietin-1 either alone or in combination.
with Vegf to support angiogenesis as a therapeutic option for the treatment of ischemic heart disease.

2. Angiopoietin-1

2.1 Angiopoietin-1 and Tie2 ligand/receptor interaction in angiogenesis

The angiopoietin family of proteins consists of four members, all of which interact with the endothelial receptor tyrosine kinase, (tunica intima endothelial kinase 2, Tie2) (Thomas & Augustin 2009). Whereas two of these factors, angiopoietin-1 and angiopoietin-4, are constitutive agonists and Tie2 receptor activators (Davis et al. 1996), angiopoietin-2 and angiopoietin-3 have different effector functions and may activate or antagonize angiopoietin-1 induced Tie2 phosphorylation (Suri et al. 1996; Valenzuela et al. 1999; Fiedler et al. 2003). The essential role of angiopoietin-1 in the expansion and stabilization of newly formed vessels has been widely demonstrated (Suri et al. 1998). The process of vasculogenesis consists of differentiation, proliferation, and coalescence of vascular endothelial cells to establish a primitive vascular network in the early stage. This is followed by maturation of the neovasculature through the process of angiogenic remodeling that involves sprouting, branching, pruning, differential growth of vessels, and the recruitment of supporting cells (Suri et al. 1998; Hattori et al. 2001).

Both angiopoietin-1 and angiopoietin-2 have discrete participation in the occurrence of angiogenic cascade wherein angiopoietin-2 accumulates at the leading edge of proliferating vessels and angiopoietin-1 shows diffused localization behind the leading edge (Suri et al. 1998). Based on this distinct pattern of expression, it is suggested that angiopoietin-2 negatively mediates Tie2 activation and destabilizes the vessels to make these responsive to other angiogenic growth factors including Vegf, Pdgf and Fgf. On the contrary, angiopoietin-1 activates Tie2 and triggers remodeling and stabilization of the newly formed vasculature which leads to its maturation (Suri et al. 1998; Huang et al. 2009). The antagonizing activity of angiopoietin-2 is imperative for normal vascular maturation and spatial configuration (Feng et al. 2009). Over expression of angiopoietin-1 results in increased number, size and branches of the blood vessels without affecting the association among endothelial cells and with no evidence of plasma leakage, edema, or erythrocyte extravasation unlike Vegf (Suri et al. 1998; Thurston et al. 1999; Thurston et al. 2000; Kim et al. 2002). Angiopoietin-1 also contributes to attenuation of inflammatory response by mediating anti-permeability effects to counter Vegf and tumor necrosis factor (TNF)-induced inflammatory molecules in the endothelial cells such as vascular adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and endothelin-1 which control cell-cell interaction, maintain vascular quiescence and prevent leakiness (Kim et al. 2002; Hughes et al. 2003; Jeon et al. 2003; McCarter et al. 2006).

Tie2 receptor, a member of receptor tyrosine kinase family, consists of an extracellular domain, a trans-membrane domain and a split intracellular kinase domain (Takahara et al. 2004). This receptor is more specifically expressed on vascular endothelium in both quiescence and active states although it is also found on some other cell types such as smooth muscle cells, fibroblasts, mural cells, ganglion cells and carcinoma cells (Dumont et al. 1992; Takahara et al. 2004; Kosacka et al. 2005; Nakayama et al. 2005; Hamaguchi et al. 2006). Tie2 is highly conserved from zebra fish to mammals with the greatest amino acid homology occurring in the kinase domain, indicating the importance of its biological function (Lyons et al. 1998). Disrupting the function of Tie2 in transgenic mice was lethal.
and resulted in early embryonic death due to failure of vascular branching and differentiation. Homozygous mutated embryos also displayed abnormalities in the development of the heart (Dumont et al. 1994; Sato et al. 1995). Lack of Tie2 also resulted in angiogenic defects in term of vessel branching and remodeling, and displayed defects in the developing vessels to have scarce peri-endothelial cells and thinner collagen-like fibers (Suri et al. 1996). Dysregulated expression of Tie2 have also been observed in several clinical diseases including venous malformations, intramuscular hemangiomas, pulmonary hypertension and infantile hemangiomas (Yu et al. 2001; Wang et al. 2004; Morris et al. 2005). On the contrary, overexpression of angiopoietin-1 in the skin of experimental animal models led to the formation of highly branched and larger vessels, and resulted in reduction of microvascular leakage (Suri et al. 1998; Thurston et al. 1999). Tie2 over expression in the skin caused psoriasis-like phenotype after birth and persisted throughout adulthood, and was featured by epidermal hyperplasia, accumulation of inflammatory cells and altered dermal angiogenesis (Voskas et al. 2005). These findings clearly suggested that a delicate level of Tie2 receptor was required for physiological functioning and any unregulated induction or loss of Tie2 resulted in potentially worsened effects. Despite considerable similarity with Tie1, experiments with Tie1- or Tie2-deficient mice have provided evidence of their distinct functions in response to different members of angiopoietin family (Seegar et al. 2011).

### 2.2 Angiopoietin-1, Tie2 receptor and intracellular signaling

It is interesting to note that angiopoietin-1 and angiopoietin-2 have different effects on vascular formation and development, however, they bind to Tie2 receptor with distinct kinetics of release following binding thus indicating that activation of Tie2 receptor is regulated independently by these two molecules. In fact, angiopoietin-2, a natural antagonist of angiopoietin-1 (Maisonpierre et al. 1997), binds to Tie2 receptor without its activation (Davis et al. 2003). Similarly, structural characteristics and distinguishable interaction with other molecules in the extracellular environment of the ligands may also essentially contribute to their counteractive properties (Kim et al. 2005). More recent studies have shown that the effects of angiopoietin-1 and angiopoietin-2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface (Hansen et al. 2010) and a critical balance is maintained between angiopoietin-1 and angiopoietin-2 expression by sonic hedgehog and fibroblast growth factor-2 during angiogenesis (Fujii & Kuwano, 2010). Phosphorylation of tyrosine residues of Tie2 occurs subsequent to binding with angiopoietin-1 and activates kinase domain of the receptor to initiate various downstream intracellular signaling cascades (Murray et al. 2001). The phosphorylation of tyrosine residues on the intracellular domain of Tie2 receptor interacts with the p85 subunit of PI3K via Src homology 2 or phosphotyrosine binding domain. These molecular changes result in activation of PI3K and its downstream Akt in the endothelial cells and ultimately lead to multiple responses such as cell survival, differentiation and chemotaxis (Witzenbichler et al. 1998; Fujikawa et al. 1999; Abdel-Malak et al. 2009; Bai et al. 2009). Although some studies have already demonstrated that angiopoietin-1 mediated activation of Tie2 does not cause mitogenesis of endothelial cells, the others have reported a pro-proliferative effect of angiopoietin-1 on vascular cells (Kanda et al. 2005; Abdel-Malak et al. 2009). These contradictions in the data may be explained on the basis of the observation that angiopoietin-1 may induce various effects on endothelial cells depending on the tissue type and conditional environments.
Angiopoietin-1 activity also involves Forkhead box O-1 (FOXO1) transcription factor which principally acts as a regulator of cell cycle and endothelial cell functions in vascular destabilization and remodeling (Kanda et al. 2005; Evans-Anderson et al. 2008). Angiopoietin-1 is known to inhibit the activity of FOXO1 via phosphorylation and promotes cell proliferation in the cultured endothelial cells by upregulation of cyclin D1 downstream of FOXO1 (Kanda et al. 2005; Huang & Tindall 2007). Phosphorylation of FOXO1 by Akt in the endothelial cells occurs at three conserved sites which results in the inhibition of FOXO1 by promoting its translocation from the nucleus to the cytoplasm (Daly et al. 2004; Huang & Tindall 2007). In addition to interaction with FOXO1, GATA3 which is highly expressed in human endothelial cells especially in the large vessels, plays a significant role in the expression of angiogenesis related genes and endothelial cell functions subsequent to stimulation with angiopoietin-1 (Song et al. 2009). Knock down of GATA3 significantly abrogated these effects of angiopoietin-1. Besides these transcription factors, angiopoietin-1 can activate MAPK in the cultured endothelial cells (Fujikawa et al. 1999; Kim et al. 2002; Zhu et al. 2002). Pharmacological inhibition of ERK1/2 abolishes Tie2 phosphorylation and its downstream signaling for morphogenesis of capillary endothelium and suppresses endothelial cell proliferation which are involved in angiogenesis (Kim et al. 2002). However, inhibition of ERK1/2 activity in endothelial cells does not effect angiopoietin-1-induced survival and migration (Fujikawa et al. 1999). Hence, it is suggested that MAPK activity as a consequence of Tie2 activation during angiogenesis is more important for endothelial sprouting and branching than for endothelial recruitment and maintenance. On the other hand, angiopoietin-1 mediated activation of p38 MAPK signaling promoted mural cell recruitment during angiogenesis (Zhu et al. 2003). Angiopoietin-1 also has the ability to directly bind to the monocytes without interacting with Tie2 and promote their transendothelial migration by directly activating PI3K for its role in inflammatory angiogenesis (Ahmad et al. 2010).

2.3 Angiopoietin-1, Tie2 receptor and extracellular response

Under physiological conditions, endothelial cells of the vasculature remain quiescent in the inner layer of vessels. However, during active vascular remodeling in response to pathological conditions like vascular occlusion, myocardial infarction or de-novo vascular formation, circulating endothelial progenitors and local endothelial cells migrate to the ischemic areas. More so, some of these cells penetrate and traverse to distant sites of the occluded vessels to participate in the repair process. Angiopoietin-2, which is mainly released by endothelial cells and localized at the site of vascular remodeling, functions as a Tie2 blocker and promotes the destabilization of pericytes from existing vessels and increases vascular permeability. This in turn allows the infiltration of proteases, cytokines and angiogenic cells to support robust angiogenic response. The blood vessels are thus formed by the complex contribution of an intricate network of smooth muscle layer that surrounds endothelial cells in arteries, arterioles and veins resulting from migration, proliferation and interaction of different cell types like pericytes, smooth muscle cells and fibroblasts (Asahara et al. 1999; Carmeliet 2000; Bentley et al. 2009). It is suggested that interaction between angiopoietin-1 and Tie2 also regulates cross-talk between endothelial cells and pericytes (Davis et al. 1996; Sundberg et al. 2002). Angiopoietin-1 is a pericyte derived signal that mediates maturation and quiescence of the microvascular endothelium (Armulik et al. 2005). In addition to its role as an effector for the secondary step of vascular formation, angiopoietin-1 can stimulate endothelial cell migration and induce angiogenesis.
Angiopoietin-1 is critical for cell survival and proliferation and functions via PI3K/Akt and MAPK/ERK signaling pathway (Daly et al. 2004; Kanda et al. 2005). ERK1/2 kinases have important role in regulation of apoptosis in various cells including endothelial cells wherein ERK1/2 have been consistently shown to mediate the anti-apoptotic effects of VEGF and angiopoietin-1 by targeting caspase-9, -3 and -7. Angiopoietin-1 also induces p38 MAPK phosphorylation as a part of its anti-apoptotic activity in the endothelial cells (Gratton et al. 2001; Harfouche et al. 2003). The pro-survival effects of angiopoietin-1 have been extensively studied in variety of cells against pro-apoptotic stimuli (Tuo et al. 2010; Lee et al. 2008; Liu et al. 2008; Bai et al. 2009). In most cases, angiopoietin-1 treatment phosphorylated Tie2 receptors leading to activation of Akt signaling. Treatment of neuronal progenitor cells with angiopoietin-1 protected the cells against oxygen-glucose deprivation induced apoptosis by activation of PI3K/Akt to inhibit pro-apoptotic signaling (Bai et al. 2009). Similarly, activation of pro-apoptotic signaling was reversed in myocardial endothelial cells in high glucose culture conditions upon treatment with angiopoietin-1 which incidentally also increased angiogenesis (Tuo et al. 2010). These salutary effects of angiopoietin-1 were however, antagonized and blunted by angiopoietin-2. Treatment with angiopoietin-1 protein or its transgenic expression in endothelial cells also induces some secondary mediators such as interleukin-8 through ERK1/2, SAPK/JNK, and PI3K pathways, which trigger c-Jun phosphorylation on Ser63 and Ser73 (Abdel-Malak et al. 2008). Interleukin-8 then acts in autocrine fashion to suppress apoptosis and facilitate cell proliferation and migration (Abdel-Malak et al. 2008).

3. Angiopoietin-1 gene delivery in combination with Vegf

Whereas Vegf is one of the most potent vasoactive growth factors which is involved in angiogenesis and regulates vascular permeability, angiopoietin-1 is also being recognized for its angiogenic potential besides its role as a vascular stability factor. Both of these growth factors are discretely produced in a succession during the development of mature blood vessels (Thurston, 2002). Angiopoietin-1 acts as a mitogen for endothelial cells and synergistically induces sprout formation with Vegf (Koblizek et al. 1998). The regulatory mechanism of angiopoietin-1 induced neovascularization involves pro-survival effects on the endothelial cells by activation of PI3K/Akt signaling and stabilization of nascent blood vessels to become leak resistant (Thurston et al. 2000).

Both Vegf and angiopoietin-1 have been extensively used for angiogenic protein or gene therapy to exploit complementarities between their functional relationship (Zhu et al. 2002; Cheng et al. 2007). Given a coordinated role of angiopoietin-1 and Vegf during both
physiologic and pathologic development of blood vessels, simultaneous use of the two growth factors have been reported for the treatment of tissue ischemia (Gale et al. 2002; Ye et al. 2007). The application of this combinatorial growth factor therapy approach is not only for induction of angiogenesis; it is also intended to involve circulating endothelial progenitor cells. These progenitors then home into the ischemic tissues in response to the concentration gradient for participation in the ongoing repair process of vasculogenesis (Kalka et al. 2000; Wang et al. 2006). We have already reported the feasibility of combining stem cell mobilization from bone marrow in combination with Vegf gene delivery to the infarcted heart to show that the mobilized stem cells homed into the heart and participated in myocardial angiogenesis (Wang et al. 2006). Although the use of recombinant growth factors has given encouraging results with both Vegf and angiopoietin-1, the very short biological half-life of these growth factors warrants alternative treatment strategies. A more recent study has reported covalent immobilization of Vegf and angiopoietin-1 onto three-dimensional porous collagen scaffolds using 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) chemistry to enhance the duration of the growth factors availability and effectiveness (Chiu & Radisic, 2011).

As an alternative to recombinant protein administration, transgenic expression of angiopoietin-1 and Vegf gene therapy is being assessed to achieve arteriogenesis and angiogenesis for the treatment of myocardial ischemia (Samuel et al. 2010; Siddiqui et al. 2003; Ye et al. 2007). The efficacy of Vegf and angiopoietin-1 gene delivery to the heart has been extensively studied to promote angiogenesis and improve regional blood flow et al. 2007; Haider, Ye et al. 2004). The authors reported the first bi-cistronic adenoviral vector encoding for Vegf and angiopoietin-1 for co-expression of the two angiogenic growth factors. The vector was used to genetically modify stem cells for overexpression of angiopoietin-1 and Vegf. Transplantation of genetically modified skeletal myoblasts demonstrated development of functionally mature blood vessels in the infarcted heart and in the hind limb ischemia model in rabbits (Niagara et al. 2004; Ye et al. 2007). These observations were in harmony with the previously published data suggesting enhanced perfusion accompanied by the development of stable and mature blood vessels with combined Vegf and angiopoietin-1 administration (Arsic et al. 2004; Gurunluoglu et al. 2002; Shyu et al. 2003). In a recently reported study, Tao et al. co-expressed Vegf/angiopoietin-1 using adeno-associated viral vectors (AAVs) expressing cardiac-specific and hypoxia-inducible Vegf and Ang1 into the porcine infarcted heart immediately after ligation of the left descending coronary artery (Tao et al. 2010). Vegf and Ang1 were predominantly expressed in the heart in the infarct and border of the infarct. Gated single-photon emission computed tomography showed improved cardiac function and myocardial perfusion at 8 weeks after vector injection which corresponded well with higher vascular density. They also observed higher level activation of Akt and Bcl-xL, less Caspase-3 and Bad, and reduced TUNEL positivity in angiopoietin-1/Vegf treated animal hearts. These results showed that simultaneous expression of angiopoietin-1/Vegf in the infarcted heart stimulated pro-survival pathways besides improved regional blood flow. Although the authors claimed to have observed significant change in the number of cycling cardiomyocytes subsequent to angiopoietin-1/Vegf overexpression, this may be insufficient to replace the massive loss of the functioning cardiomyocytes in the infarcted heart. Although direct injection of angiopoietin-1 and Vegf growth factors has been shown to significantly improve the regional blood flow in the ischemic heart, this strategy if combined with stem cell therapy would be more effective in addressing the core issue of myocardial regeneration which requires neomyogenesis for replacement of the scar tissue.
4. Combining stem cell transplantation and Angiopoietin-1 delivery

Gene delivery strategy has developed over the years from direct plasmid injection to stem cell based ex-vivo delivery strategy. Stem cells are excellent carriers of therapeutic genes for delivery to the various body tissues and organs including the heart (Suzuki et al. 2001; Yau et al. 2007; Ye et al. 2007; Haider et al. 2008). Despite all the progress made, it remains to be defined whether cell based gene therapy can overcome several potential impediments such as poor transfection efficiency, unregulated transgene expression, low survival rate of transplanted cells into ischemic zones etc. On the same note, there are a number of parameters which require optimization including cell type, number of transfected cells to be transplanted, time of cell transplantation after infarction, and route of cell transplantation. Angiopoietin-1 is one of the many angiogenic growth factors which have been extensively studied for pro-angiogenic activity in the ischemic tissues. We performed a comparative assessment of the methods to deliver angiopoietin-1 gene delivery for angiogenic repair of the infarcted heart using an experimental porcine heart model of chronic infarction (Ye et al. 2007). Our results showed that skeletal myoblast based delivery of angiopoietin-1 transgene was more effective as compared to the approach of direct injection of adenoviral vector encoding for angiopoietin-1. The genetically modified skeletal myoblasts carrying angiopoietin-1 transgene served as a reservoir of the transgene product and ensured localized release of angiopoietin-1 at the site of the cell graft without safety concerns associated with the use of direct injection of adenoviral vector (Ye et al. 2007). Besides we observed extensive survival of the transplanted skeletal myoblasts which underwent myogenic differentiation to repopulate the infarcted myocardium. Given that the development of stable and functional blood vessels is regulated by a critical balance between several pro- and anti-angiogenic factors which also co-ordinate with various vasculogenic cells, we hypothesized that a single angiogenic factor may be insufficient to achieve the desired outcome. We therefore opted to combine angiopoietin-1 and Vegf for co-expression to achieve angiogenic synergism between the two growth factors (Ye et al. 2007). We developed a bicistronic adenoviral vector which encoded for human Vegf165 and angiopoietin-1 driven by the same promoter. The vector was used to genetically modify human skeletal myoblasts which were later transplanted in a porcine heart model of coronary artery ligation. We observed excellent survival of the transplanted skeletal myoblasts for up to 12 weeks using transient immunosuppression. Immunohistological studies showed myogenic differentiation of the skeletal myoblasts and increased blood vessel density in the infarct as well as peri-infarct regions with highest maturation index in the animal heart treated with skeletal myoblasts co-expressing Vegf and angiopoietin-1. Regional blood flow, measured with fluorescent microspheres, was significantly improved which revealed the functional competence of the newly formed blood vessels. These findings signified the feasibility of multimodal therapeutic approach based on simultaneous delivery of angiopoietin-1 and Vegf combined with cell transplantation. Although skeletal myoblasts showed excellent ability as transgene carriers, one of the major drawbacks is their failure to develop gap junctions with the host cardiomyocytes and arrhythmogenicity (Fouts et al. 2006). We therefore hypothesized that the use of bone marrow derived mesenchymal stem cells might be a better option. Mesenchymal stem cells have been extensively studied for their cardiac reparability and regenerative potential (Chen et al. 2010; Kim et al 2010.; Labovsky et al. 2010; Haider et al. 2009) besides having superior transgene carrying capability (Chen et al. 2010; Huang et al. 2010; Tang et al. 2010; Haider et
Besides, we also opted to replace Vegf with survival signaling molecule Akt to support survival of the genetically modified mesenchymal stem cells (Jiang et al. 2006). Our choice of transgene combination of angiopoietin-1 and Akt achieved maximum beneficial effects in terms of donor stem cell survival and angiomyogenic repair of the infarcted heart. More importantly, the therapeutic benefits in terms of cell graft survival, stability of newly formed blood vessels and global cardiac function were stable for up to 3 months (Shujia et al. 2008). A more recent study has used sendai viral vector for transduction of mesenchymal stem cells, however, it remains difficult to see the advantages of mesenchymal stem cells modified with sendai vector harboring human angiopoietin-1 gene (Piao, Wang et al.)

5. Conclusions

Genetic modification increases the therapeutic efficacy of stem cells by improving their survival, enhancement of paracrine activity and by supporting their angiomyogenic differentiation (Tang et al. 2004). A combined cell and gene therapy approach reverses the deteriorating function of the infarcted heart (Mangi et al. 2003; Matsumoto et al. 2005) and offers an extended and localized expression of the transgene product. From the clinical standpoint, the strength of stem cell therapy and gene therapy approaches lies in their combined application to achieve stable therapeutic benefits. The viability and persistence of the genetically modified stem cells and their derivative graft in the heart can be significantly enhanced by restoration of regional blood flow via biological bypass surgery which is achieved by neovascularization of the infarcted heart. The new emerging pro-angiogenic role of angiopoietin-1 independent of VEGF, in addition to its well recognized participation in the angiogenic cascade as a maturation factor, makes angiopoietin-1 as a growth factor of choice for ex-vivo stem cell based gene therapy which can be used independently or in combination with VEGF to support angiomyogenic recovery of the infarcted heart.

6. Acknowledgements

This work was supported by National Institutes of Health Grants #R37-HL074272; HL-080686; HL-087246(M.A) and HL-087288; HL-089535; HL106190-01 (Kh.H.H).

7. References


www.intechopen.com


www.intechopen.com


Kim SK, Pak HN, Park JH, Fang YF, Kim GI, Park YD, Hwang C, Kim YH, Kim BS. Cardiac cell therapy with mesenchymal stem cell induces cardiac nerve sprouting, angiogenesis, and reduced connexin43-positive gap junctions, but concomitant electrical pacing increases connexin43-positive gap junctions in canine heart. *Cardiol Young* 20(3): 308-17.


Angiopoietin-1 for Myocardial Angiogenesis


Myocarditis, the inflammation of the heart muscle, could be in some cases serious and potentially fatal disease. This book is a comprehensive compilation of studies from leading international experts on various aspects of myocarditis. The first section of the book provides a clinical perspective on the disease. It contains comprehensive reviews of the causes of myocarditis, its classification, diagnosis, and treatment. It also includes reviews of Perimyocarditis; Chagasâ€™ chronic myocarditis, and myocarditis in HIV-positive patients. The second section of the book focuses on the pathogenesis of myocarditis, discussing pathways and mechanisms activated during viral infection and host immune response during myocarditis. The third, and final, section discusses new findings in the pathogenesis that may lead to new directions for clinical diagnosis, including use of new biomarkers, and new treatments of myocarditis.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:


InTech Europe
University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821